China Pharma Holdings Inc

Healthcare US CPHI

0.881USD
0.02(2.48%)

Last update at 2026-06-03T20:00:00Z

Day Range

0.780.88

LowHigh

52 Week Range

0.502.60

LowHigh

Fundamentals

Previous Close 0.86
Market Cap26.59M
Volume45859
P/E Ratio-
Dividend Yield-%
EBITDA-1.58389M
Revenue TTM4.14M
Revenue Per Share TTM0.97
Gross Profit TTM -0.13195M
Diluted EPS TTM-0.74

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-3.18756M	-4.73637M	-3.07882M	-3.97284M	-3.39948M
Minority interest	-	-	-	-	-
Net income	-3.18756M	-4.73637M	-3.07882M	-10.22163M	-3.94148M
Selling general administrative	2.45M	1.78M	1.47M	1.89M	1.65M
Selling and marketing expenses	0.38M	0.53M	0.78M	1.07M	1.50M
Gross profit	-0.13195M	-1.98565M	-0.28108M	-0.49392M	0.35M
Reconciled depreciation	1.58M	2.62M	2.70M	2.70M	3.09M
Ebit	-3.08552M	-4.58223M	-2.74522M	-3.54898M	-3.11572M
Ebitda	-1.50635M	-1.96416M	0.00844M	-0.84844M	-0.02487M
Depreciation and amortization	1.58M	2.62M	2.75M	2.70M	3.09M
Non operating income net other	-	-	-	-	-
Operating income	-3.08854M	-4.58887M	-2.75182M	-3.54898M	-3.11572M
Other operating expenses	7.23M	9.12M	9.76M	5.54M	12.76M
Interest expense	0.10M	0.15M	0.33M	-0.42386M	0.54M
Tax provision	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Interest income	0.00200M	0.00664M	0.00507M	0.01M	0.00303M
Net interest income	-0.10003M	-0.14750M	-0.37445M	-0.42386M	-0.53897M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-4736360.26364M	-0.00000M	6.25M	0.54M
Total revenue	4.14M	4.53M	7.01M	8.10M	9.64M
Total operating expenses	2.96M	2.60M	2.47M	3.15M	3.46M
Cost of revenue	4.28M	6.51M	7.29M	8.60M	9.29M
Total other income expense net	-0.09902M	-0.14750M	-0.32700M	-0.42386M	-0.28375M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-3.18756M	-4.73637M	-3.11079M	-3.97284M	-3.39948M
Net income applicable to common shares	-	-	-	-	-3.39948M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	30999464.00M	14.89M	16.47M	17.78M	22.65M
Intangible assets	24079265.00M	7.09M	3.65M	2.21M	0.59M
Earning assets	-	-	-	-	-
Other current assets	379871.71M	0.10M	0.11M	0.57M	0.06M
Total liab	8259712.00M	7.14M	9.01M	13.49M	16.63M
Total stockholder equity	22739752.00M	7.75M	7.45M	4.29M	6.02M
Deferred long term liab	-	-	-	-	-
Other current liab	7328730.04M	1.83M	1.55M	2.79M	2.18M
Common stock	15522.00M	0.03M	0.01M	0.07M	0.05M
Capital stock	0.02M	0.03M	0.01M	0.07M	0.05M
Retained earnings	-47214235.00000M	-44.02668M	-39.29031M	-36.21150M	-32.23866M
Other liab	-	-	-	-	0.82M
Good will	-	-0.39184M	0.40M	-	-
Other assets	-	-3270385.54961M	-	-	-
Cash	345112.00M	0.63M	1.42M	2.03M	4.86M
Cash and equivalents	-	-	-	-	-
Total current liabilities	7400359.00M	5.02M	6.82M	12.74M	10.51M
Current deferred revenue	-	0.16M	0.09M	0.52M	0.21M
Net debt	-161936.00000M	2.96M	3.21M	6.73M	7.63M
Short term debt	71628.07M	2.20M	3.18M	8.76M	7.19M
Short long term debt	3.70M	2.16M	3.10M	8.72M	7.11M
Short long term debt total	183176.00M	3.59M	4.63M	8.76M	12.49M
Other stockholder equity	58355877.54M	40.42M	35.28M	28.85M	25.65M
Property plant equipment	-	-	-	-	13.41M
Total current assets	2346407.00M	3.27M	6.00M	5.96M	9.09M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	-	5.87M
Short term investments	-	626878.37M	0.07M	-	-
Net receivables	0.29M	0.28M	0.73M	0.46M	0.84M
Long term debt	-	1.39M	1.41M	-	5.25M
Inventory	1621423.00M	2.27M	3.73M	2.95M	3.34M
Accounts payable	0.89M	0.23M	0.97M	0.67M	0.93M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	11582646.00M	11.32M	11.45M	11.57M	12.56M
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-0.18000M	0.39M	-0.39768M	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	28653057.00M	11.62M	10.47M	11.82M	13.56M
Capital lease obligations	0.18M	0.04M	0.12M	0.04M	0.13M
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-	-0.29172M	0.02M	-0.40196M	-0.43806M
Change to liabilities	-	-	-	-	-0.85319M
Total cashflows from investing activities	-0.13725M	-0.29172M	-0.01152M	-	-0.43806M
Net borrowings	-0.29403M	0.03M	0.07M	-	4.60M
Total cash from financing activities	-0.29403M	0.03M	0.07M	-1.77001M	4.60M
Change to operating activities	-	-	-	-	0.44M
Net income	-3.18756M	-4.73637M	-3.07882M	-3.97284M	-3.39948M
Change in cash	-0.28177M	-0.79696M	-0.60613M	-2.82909M	3.90M
Begin period cash flow	0.63M	1.42M	2.03M	4.86M	0.96M
End period cash flow	0.35M	0.63M	1.42M	2.03M	4.86M
Total cash from operating activities	0.15M	-0.46636M	-0.69969M	-0.40954M	-0.24984M
Issuance of capital stock	-	-	-	-	-
Depreciation	1.58M	2.62M	2.75M	2.70M	3.09M
Other cashflows from investing activities	-0.07793M	-0.25331M	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	0.59M	1.61M	-0.01706M	0.69M	1.01M
Change to account receivables	13.21M	-0.19771M	-0.93802M	-0.17019M	-0.10692M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-294027.00000M	27352.97M	-0.01152M	-1.11353M	10.01M
Change to netincome	-	-	-	-	-0.23997M
Capital expenditures	0.14M	0.29M	0.01M	0.40M	0.44M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	14.87M	1.20M	-0.39617M	0.88M	0.05M
Stock based compensation	-	-	0.00000M	0.08M	0.02M
Other non cash items	-13.11327M	0.46M	0.02M	-0.09385M	0.25M
Free cash flow	0.01M	-0.75808M	-0.71120M	-0.81151M	-0.68789M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
CPHI China Pharma Holdings Inc	0.02 2.48%	0.88	-	1.56	6.42	1.19	7.36	-225.8917
ZTS Zoetis Inc	1.20 1.57%	77.59	40.18	30.96	10.67	17.60	11.27	26.18
MKKGY Merck KGaA ADR	0.58 1.91%	31.01	21.25	14.93	3.10	2.14	3.60	12.98
MKGAF MERCK Kommanditgesellschaft auf Aktien	- -%	153.91	21.73	14.95	3.16	2.15	3.56	12.82
GALDY GALDERMA GROUP AG	-0.79 1.89%	40.92	74.21	41.67	8.64	5.55	9.15	42.22

Reports Covered

View All

Profile

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

China Pharma Holdings Inc

No. 17, Jinpan Road, Haikou, China, 570216

86 89 8668 11730
https://www.chinapharmaholdings.com
Employees : 215

Key Executives

Name	Title	Year Born
Ms. Zhilin Li	Pres, CEO, Chairman & Interim CFO	1953
Ms. Huang Na C.F.A.	BOD Sec. & IR Mang.	NA
Sam Hsing	Corp. VP	NA
Ms. Zhilin Li	President, CEO, Chairman & Interim CFO	1953
Ms. Huang Na C.F.A.	BOD Secretary & IR Manager	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.